Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | CHKA | P35790 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridine SCHEMBL2544321 | 0.81 | TSHR (0.45) | TSHRNAPRTTDP1MAPTNPSR1 | |
| Pyridine SCHEMBL9577788 | 0.80 | TSHR (0.60) | TSHRNAPRTTDP1MAPTNPSR1 | |
| Methenamine SCHEMBL28834492 | 0.80 | TSHR (0.60) | TSHRNAPRTTDP1NOTUM | |
| SCHEMBL3052767 | 0.78 | TSHR (1.00) | TSHRNAPRTTDP1MAPTNOTUM | |
| Pyridine SCHEMBL16 | 0.78 | — | — | |
| Benzene SCHEMBL10751789 | 0.78 | TSHR (1.00) | TSHRNAPRTTDP1MAPTNOTUM | |
| Pyridine SCHEMBL933604 | 0.78 | TSHR (1.00) | TSHRNAPRTTDP1MAPTNOTUM | |
| Pyridine SCHEMBL9037865 | 0.78 | TSHR (1.00) | TSHRNAPRTTDP1MAPTNOTUM | |
| Benzene SCHEMBL1261317 | 0.78 | TSHR (1.00) | TSHRNAPRTTDP1MAPTNOTUM | |
| Pyridine SCHEMBL1654468 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115677443-B | Method for constructing 1, 4-diketone compound by olefin 1, 2-dicarbonylation | 中国科学院理化技术研究所 | 2024-07-16 | — | — | CN | claimed |
| US-7459470-B2 | N-oxide anthranylamide derivatives and their use as medicaments | SCHERING AG (DE) | 2008-12-02 | — | — | US | disclosed |
| US-7429592-B2 | Cyanoanthranilamide derivatives and the use thereof as medicaments | SCHERING AKTIENEGESELLSCHAFT (DE) | 2008-09-30 | — | — | US | disclosed |
| CN-1309704-C | Anthranilic acid amides and their use as medicaments | SCHERING AG (DE) | 2007-04-11 | — | — | CN | disclosed |
| US-7012081-B2 | Anthranyl amides and their use as medicaments | SCHERING AG (DE) | 2006-03-14 | — | — | US | disclosed |
| US-20050261343-A1 | Anthranilamides and their use as pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-11-24 | — | — | US | disclosed |
| US-20050032816-A1 | N-oxide anthranylamide derivatives and their use as medicaments | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-02-10 | — | — | US | disclosed |
| US-20040266770-A1 | Cyanoanthranilamide derivatives and the use thereof as medicaments | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-12-30 | — | — | US | disclosed |
| US-20040029880-A1 | Anthranyl amides and their use as medicaments | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-02-12 | — | — | US | disclosed |
| CN-1429200-A | Anthranilic acid amides and their use as medicaments | SCHERING AG (DE) | 2003-07-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261343-A1 | Anthranilamides and their use as pharmaceutical agents | AADAC, ANTXR2, VEGFA | TSHR 3635/4885NAPRT 200/4885TDP1 4664/4885 |
| US-20050032816-A1 | N-oxide anthranylamide derivatives and their use as medicaments | FLT4, KDR, NOS3 | TSHR 2967/4885NAPRT 1179/4885TDP1 4181/4885 |
| US-20040029880-A1 | Anthranyl amides and their use as medicaments | AADAC, ANTXR2, VEGFA | TSHR 3677/4885NAPRT 164/4885TDP1 4810/4885 |
| US-20040266770-A1 | Cyanoanthranilamide derivatives and the use thereof as medicaments | FLT4, KDR, FLT1 | TSHR 2690/4885NAPRT 2040/4885TDP1 3724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.